NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing DOI Creative Commons
Wei Feng, Joanne C. Beer, Qinyu Hao

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Nov. 9, 2023

The blood proteome holds great promise for precision medicine but poses substantial challenges due to the low abundance of most plasma proteins and vast dynamic range proteome. Here we address these with NUcleic acid Linked Immuno-Sandwich Assay (NULISA™), which improves sensitivity traditional proximity ligation assays by ~10,000-fold attomolar level, suppressing assay background via a dual capture release mechanism built into oligonucleotide-conjugated antibodies. Highly multiplexed quantification both low- high-abundance spanning wide is achieved attenuating signals from abundant targets unconjugated antibodies next-generation sequencing barcoded reporter DNA. A 200-plex NULISA containing 124 cytokines chemokines other demonstrates superior extension in detecting biologically important low-abundance biomarkers patients autoimmune diseases COVID-19. Fully automated makes broad in-depth proteomic analysis easily accessible research diagnostic applications.

Language: Английский

Liquid biopsy enters the clinic — implementation issues and future challenges DOI
Michail Ignatiadis, George W. Sledge, Stefanie S. Jeffrey

et al.

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 18(5), P. 297 - 312

Published: Jan. 20, 2021

Language: Английский

Citations

880
Kinase drug discovery 20 years after imatinib: progress and future directions DOI Open Access
Philip Cohen, Darren A.E. Cross, Pasi A. Jänne

et al.

Nature Reviews Drug Discovery, Journal Year: 2021, Volume and Issue: 20(7), P. 551 - 569

Published: May 17, 2021

Language: Английский

Citations

801
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention DOI Open Access
Anne Marie Lennon, Adam H. Buchanan,

Isaac Kinde

et al.

Science, Journal Year: 2020, Volume and Issue: 369(6499)

Published: April 28, 2020

A real-time trial of a cancer blood test Cancers diagnosed early are often more responsive to treatment. Blood tests that detect molecular markers have successfully identified individuals already known the disease. Lennon et al. conducted an exploratory study closely reflects way in which such would be used future. They evaluated feasibility and safety incorporating multicancer into routine clinical care 10,000 women with no history cancer. Over 12-month period, detected 26 cancers different types. combination positron emission tomography–computed tomography (PET-CT) imaging led surgical removal nine these cancers. Use did not result large number futile follow-up procedures. Science , this issue p. eabb9601

Language: Английский

Citations

510
Immune checkpoint therapy—current perspectives and future directions DOI
Padmanee Sharma, Sangeeta Goswami,

Deblina Raychaudhuri

et al.

Cell, Journal Year: 2023, Volume and Issue: 186(8), P. 1652 - 1669

Published: April 1, 2023

Language: Английский

Citations

502
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer DOI Creative Commons
Christian Rolfo, Philip C. Mack, Giorgio V. Scagliotti

et al.

Journal of Thoracic Oncology, Journal Year: 2021, Volume and Issue: 16(10), P. 1647 - 1662

Published: July 8, 2021

Language: Английский

Citations

458
Metastasis DOI Creative Commons

Stefanie Gerstberger,

Qingwen Jiang, Karuna Ganesh

et al.

Cell, Journal Year: 2023, Volume and Issue: 186(8), P. 1564 - 1579

Published: April 1, 2023

Language: Английский

Citations

383
Overcoming therapy resistance in EGFR-mutant lung cancer DOI
Antonio Passaro, Pasi A. Jänne, Tony Mok

et al.

Nature Cancer, Journal Year: 2021, Volume and Issue: 2(4), P. 377 - 391

Published: April 15, 2021

Language: Английский

Citations

368
Evaluation of cell-free DNA approaches for multi-cancer early detection DOI Creative Commons

Arash Jamshidi,

Minetta C. Liu, Eric A. Klein

et al.

Cancer Cell, Journal Year: 2022, Volume and Issue: 40(12), P. 1537 - 1549.e12

Published: Nov. 17, 2022

In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining clinical limit of (LOD) based on tumor allele fraction (cTAF), enabling performance comparisons. Among 10 machine-learning classifiers trained same samples and independently validated, when evaluated at 98% specificity, those using whole-genome (WG) methylation, single nucleotide variants with paired white blood cell background removal, combined scores from in this study show highest cancer signal sensitivities. Compared stage type, cTAF is more significant predictor classifier may closely reflect biology. Clinical LODs mirror relative sensitivities all approaches. The WG methylation feature best predicts origin. most promising technology MCED informs development targeted test.

Language: Английский

Citations

189
Tumor biomarkers for diagnosis, prognosis and targeted therapy DOI Creative Commons
Yue Zhou, Lei Tao, Jiahao Qiu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: May 20, 2024

Abstract Tumor biomarkers, the substances which are produced by tumors or body’s responses to during tumorigenesis and progression, have been demonstrated possess critical encouraging value in screening early diagnosis, prognosis prediction, recurrence detection, therapeutic efficacy monitoring of cancers. Over past decades, continuous progress has made exploring discovering novel, sensitive, specific, accurate tumor significantly promoted personalized medicine improved outcomes cancer patients, especially advances molecular biology technologies developed for detection biomarkers. Herein, we summarize discovery development including history conventional innovative used biomarker classification biomarkers based on tissue origins, application clinical management. In particular, highlight recent advancements biomarker-based anticancer-targeted therapies emerging as breakthroughs promising strategies. We also discuss limitations challenges that need be addressed provide insights perspectives turn into opportunities this field. Collectively, multiple emphasized review may guidance precision medicine, broaden horizons future research directions, expedite patients according their rather than organs origin.

Language: Английский

Citations

179
Bioactive DNA from extracellular vesicles and particles DOI Creative Commons
Ethan Z. Malkin, Scott V. Bratman

Cell Death and Disease, Journal Year: 2020, Volume and Issue: 11(7)

Published: July 27, 2020

Abstract Extracellular vesicles (EVs) and particles (EPs) have recently emerged as active carriers of molecular biomarkers mediators intercellular communication. While most investigations focused exclusively on the protein, lipid RNA constituents these extracellular entities, EV/EP DNA remains poorly understood, despite being found in association with virtually all populations. The functional potential has been proposed a number pathological states, including malignancies autoimmune diseases. Moreover, effectiveness cell-free biomarker choice emerging liquid biopsy applications highlights role that may play novel disease biomarker. In this review, we provide comprehensive overview studies conducted to date, particular focus roles mediator various pathologic states. We also review what is currently known about origins, structure, localisation distribution DNA, highlighting current controversies well opportunities for future investigation.

Language: Английский

Citations

174